Subtopic Deep Dive

Hawthorn Extract Cardiovascular Pharmacology
Research Guide

What is Hawthorn Extract Cardiovascular Pharmacology?

Hawthorn extract cardiovascular pharmacology studies the positive inotropic, vasodilatory, and antiarrhythmic effects of Crataegus spp. extracts in heart failure models via flavonoids and procyanidins.

Researchers examine hawthorn (Crataegus oxyacantha) for treating mild heart failure through randomized clinical trials and preclinical models. Key reviews cover pharmacology, efficacy, and safety (Rigelsky and Sweet, 2002; 204 citations). Over 10 major papers since 2002 analyze its roles in hypertension, hyperlipidemia, and atherosclerosis (Chang et al., 2005; 157 citations).

Curated Papers

Key Challenges

Why It Matters

Hawthorn extracts support mild heart failure management as an adjunct to standard therapy, shown in the HERB CHF trial where it increased submaximal exercise capacity (Zick et al., 2009; 59 citations). Standardized leaf-flower extracts improve cardiac function in NYHA class II-III patients (Koch and Malek, 2011; 64 citations). Extracts reduce atherosclerosis via anti-inflammatory flavonoids, offering herbal alternatives amid rising CVD prevalence (Wu et al., 2020; 91 citations). Clinical use requires monitoring digoxin interactions (Tankanow et al., 2003; 66 citations).

Key Research Challenges

Standardization of Extracts

Variability in flavonoid and procyanidin content across Crataegus species complicates reproducible efficacy (Kumar et al., 2012). Hydroalcoholic leaf-flower extracts show consistency in trials, but fruit extracts differ (Koch and Malek, 2011). Lack of uniform markers hinders comparisons (Rigelsky and Sweet, 2002).

Drug Interaction Risks

Flavonoids inhibit P-glycoprotein, raising digoxin plasma levels by 20-30% in interaction studies (Tankanow et al., 2003). Limited data on combinations with beta-blockers or ACE inhibitors persists (Chang et al., 2005). Safety in polypharmacy needs more RCTs.

Long-term Clinical Efficacy

Short-term trials like HERB CHF show exercise benefits, but 2-year mortality data is inconclusive (Zick et al., 2009). Meta-analyses needed for NYHA class progression (Furey et al., 2010). Dose-response curves remain undefined (Wang et al., 2013).

Essential Papers

Hawthorn: Pharmacology and therapeutic uses

Janene M. Rigelsky, Burgunda V. Sweet · 2002 · American Journal of Health-System Pharmacy · 204 citations

The uses, pharmacology, clinical efficacy, dosage and administration, adverse effects, and drug interactions of hawthorn are discussed. Hawthorn (Crataegus oxyacantha) is a fruit-bearing shrub with...

Hawthorn: Potential Roles in Cardiovascular Disease

Wei‐Tien Chang, Jenny Dao, Zuo‐Hui Shao · 2005 · The American Journal of Chinese Medicine · 157 citations

Hawthorn (Crataegus) may play a role in the prevention and treatment of cardiovascular diseases such as hypertension, hyperlipidemia, and in particular, congestive heart failure. Evidence is accumu...

Hawthorn (Crataegus spp.) in the treatment of cardiovascular disease

Ambrose Furey, MaryC Tassell, Rosari Kingston et al. · 2010 · Pharmacognosy Reviews/Bioinformatics Trends/Pharmacognosy review · 141 citations

The medicinal properties of hawthorn (Crataegus spp., a genus comprising approximately 300 species) have been utilized by many cultures for a variety of therapeutic purposes for many centuries. In ...

The genus Crataegus: chemical and pharmacological perspectives

Dinesh Kumar, Vikrant Arya, Zulfiqar Ali Bhat et al. · 2012 · Revista Brasileira de Farmacognosia · 121 citations

Traditional drugs have become a subject of world importance, with both medicinal and economical implications. A regular and widespread use of herbs throughout the world has increased serious concer...

Effect of<i>Crataegus</i>Usage in Cardiovascular Disease Prevention: An Evidence-Based Approach

Jie Wang, Xing-Jiang Xiong, Bo Feng · 2013 · Evidence-based Complementary and Alternative Medicine · 119 citations

Hawthorn ( Crataegus oxyacantha ) is a widely used Chinese herb for treatment of gastrointestinal ailments and heart problems and consumed as food. In North America, the role of treatment for heart...

Hawthorn (Crataegus spp.): An Updated Overview on Its Beneficial Properties

Amirhossein Nazhand, Massimo Lucarini, Alessandra Durazzo et al. · 2020 · Forests · 110 citations

Medicinal plants, many of which are wild, have recently been under the spotlight worldwide due to growing requests for natural and sustainable eco-compatible remedies for pathological conditions wi...

Roles and Mechanisms of Hawthorn and Its Extracts on Atherosclerosis: A Review

Min Wu, Longtao Liu, Yanwei Xing et al. · 2020 · Frontiers in Pharmacology · 91 citations

Cardiovascular disease (CVD), especially atherosclerosis, is a leading cause of morbidity and mortality globally; it causes a considerable burden on families and caregivers and results in significa...

Reading Guide

Foundational Papers

Read Rigelsky and Sweet (2002; 204 citations) first for pharmacology overview, then Chang et al. (2005; 157 citations) for CVD mechanisms, followed by Furey et al. (2010; 141 citations) for clinical synthesis.

Recent Advances

Study Nazhand et al. (2020; 110 citations) for updated properties, Wu et al. (2020; 91 citations) for atherosclerosis mechanisms.

Core Methods

Core techniques: standardized hydroalcoholic extracts in RCTs (Koch and Malek, 2011), digoxin PK interaction assays (Tankanow et al., 2003), exercise tolerance trials (Zick et al., 2009).

How PapersFlow Helps You Research Hawthorn Extract Cardiovascular Pharmacology

Discover & Search

Research Agent uses searchPapers with 'hawthorn extract heart failure RCT' to retrieve Rigelsky and Sweet (2002; 204 citations), then citationGraph maps 200+ citing works on Crataegus pharmacology. exaSearch scans preprints for unpublished trials; findSimilarPapers links to Chang et al. (2005) for anti-ischemic mechanisms.

Analyze & Verify

Analysis Agent applies readPaperContent to extract flavonoid mechanisms from Koch and Malek (2011), then verifyResponse with CoVe cross-checks claims against Zick et al. (2009) HERB CHF data. runPythonAnalysis computes meta-effect sizes from trial outcomes using pandas; GRADE grading scores evidence as moderate for NYHA II-III efficacy.

Synthesize & Write

Synthesis Agent detects gaps in long-term atherosclerosis data (Wu et al., 2020), flags contradictions between digoxin studies (Tankanow et al., 2003). Writing Agent uses latexEditText for review drafting, latexSyncCitations integrates Rigelsky (2002), and latexCompile generates PDF; exportMermaid diagrams flavonoid pathways.

Use Cases

"Run meta-analysis on hawthorn RCTs for ejection fraction improvement"

Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas meta-analysis on Zick 2009 + Koch 2011 data) → CSV export of forest plot stats.

"Write LaTeX review on hawthorn standardization challenges"

Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations (Kumar 2012, Rigelsky 2002) → latexCompile → peer-ready PDF.

"Find code for simulating hawthorn flavonoid pharmacokinetics"

Research Agent → paperExtractUrls → Code Discovery → paperFindGithubRepo → githubRepoInspect → Python sandbox verification of PK models.

Automated Workflows

Deep Research workflow conducts systematic review: searchPapers (50+ hawthorn papers) → citationGraph → GRADE grading → structured report on CVD efficacy. DeepScan applies 7-step analysis with CoVe checkpoints to verify Zick (2009) trial against Rigelsky (2002) pharmacology. Theorizer generates hypotheses on procyanidin antiarrhythmic mechanisms from Chang (2005) and Wu (2020).

Try Doxa for Hawthorn Extract Cardiovascular Pharmacology Research

Frequently Asked Questions

What defines hawthorn extract cardiovascular pharmacology?

It examines Crataegus spp. extracts' inotropic, vasodilatory, and antiarrhythmic actions in heart failure via flavonoids and procyanidins (Rigelsky and Sweet, 2002).

What are main methods in hawthorn studies?

Methods include RCTs like HERB CHF for exercise capacity (Zick et al., 2009), preclinical ischemia models (Chang et al., 2005), and interaction pharmacokinetics (Tankanow et al., 2003).

What are key papers?

Rigelsky and Sweet (2002; 204 citations) reviews pharmacology; Zick et al. (2009; 59 citations) reports RCT; Koch and Malek (2011; 64 citations) covers standardized extracts.

What open problems exist?

Challenges include extract standardization (Kumar et al., 2012), long-term outcomes beyond 6 months (Furey et al., 2010), and interactions with modern CVD drugs.